Research Articles | Page 29 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy Oct 2023 Annual Review of Pathology: Mechanisms of Disease Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Journey from Blood Cells to Genes and Back Aug 2023 Annual Review of Genomics and Human Genetics Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Nov 2020 Annals of Oncology: Official Journal of the European Society for Medical Oncology Myelodysplastic Syndromes (MDS)
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes Oct 2020 Annals of internal medicine Myelodysplastic Syndromes (MDS)
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series Jan 2021 Annals of Hematology Aplastic Anemia
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion Oct 2019 Annals of Hematology Myelodysplastic Syndromes (MDS)
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia Jul 2023 Annals of Hematology Aplastic Anemia
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry Jul 2020 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Evolving therapies for lower-risk myelodysplastic syndromes Apr 2020 Annals of Hematology Myelodysplastic Syndromes (MDS)
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Oct 2023 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)